Breast Cancer
Conditions
Keywords
stage IV breast cancer, stage I breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, male breast cancer
Brief summary
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) using ferumoxtran-10, may help find and diagnose breast cancer that may have spread to the axillary lymph nodes and may help in planning breast cancer treatment. PURPOSE: This phase II trial is studying how well MRI using ferumoxtran-10 works in finding metastases to the axillary lymph nodes in patients with invasive breast cancer.
Detailed description
OBJECTIVES: Primary * Determine the utility of magnetic resonance (MR) imaging using ferumoxtran-10 in identifying metastases to the axillary lymph nodes in patients with invasive breast cancer. Secondary * Determine the changes in MR T1 and T2 signal intensity in primary breast tumors after administration of this drug to these patients. * Determine the potential of delayed imaging, in terms of defining tumor boundaries, in these patients. OUTLINE: Patients receive ferumoxtran-10 IV over 25-30 minutes on day 0 in the absence of unacceptable toxicity. Patients undergo MRI of the involved breast and ipsilateral axilla on day 0 (once before and once after ferumoxtran-10 administration) and then once on day 1. Within 3 weeks after the completion of imaging studies, patients undergo sentinel lymph node biopsy. If the sentinel node is positive for malignancy on touch prep, an axillary lymph node dissection is performed if clinically indicated. Patients are followed at approximately 1 month after surgery. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within 8.3 months.
Interventions
Sponsors
National Cancer Institute (NCI)
Virginia Commonwealth University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed invasive breast cancer * Candidate for sentinel lymph node biopsy and/or axillary lymph node dissection * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Age * 18 and over Sex * Male or female Menopausal status * Not specified Performance status * Not specified Life expectancy * Not specified Hematopoietic * WBC ≥ 3,000/mm\^3 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count \> 100,000/mm\^3 * Ferritin ≤ 350 ng/mL\* * Transferrin saturation level ≤ 40%\* NOTE: \*Patients with lab values above these limits may be eligible provided there is no hemochromatosis by hematology consultation Hepatic * Bilirubin normal * AST and ALT ≤ 2.5 times upper limit of normal * Alkaline phosphatase normal * PT normal * Albumin normal * No history of cirrhosis Renal * Creatinine normal OR * Creatinine clearance \> 60 mL/min Cardiovascular * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia Other * Not pregnant or nursing * Negative pregnancy test * Medically stable * No ongoing or active infection * No history of allergic reaction attributed to compounds of similar chemical or biological composition to ferumoxtran-10 (e.g., iron preparations, parenteral iron, parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide preparations) * No history of allergic reaction to any contrast media * No immunodeficiency that would predispose patient to a specific or non-specific mediator release * No contraindication to MRI, including any of the following: * Severe claustrophobia * Pacemaker * Aneurysm clips * Defibrillators * Certain types of replacement joints * Other institutional contraindication to MRI * No psychiatric illness or social situation that would preclude study compliance * No other uncontrolled illness PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified Other * More than 30 days since prior investigational agents * More than 3 months since prior ferumoxides
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Utility of magnetic resonance imaging using ferumoxtran-10 in identifying metastases to axillary lymph nodes | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Changes in MR T1 and T2 signal intensity | 2 years |
Countries
United States
Outcome results
None listed